BMS-790052 对 HCV 基因 4 型 NS5A 的体外活性。
In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.
机构信息
Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA.
出版信息
Antimicrob Agents Chemother. 2012 Mar;56(3):1588-90. doi: 10.1128/AAC.06169-11. Epub 2011 Dec 27.
Abstract
The antiviral profile of BMS-790052, a potent hepatitis C virus (HCV) replication complex inhibitor targeting nonstructural protein NS5A, is well characterized for HCV genotype-1. Here, we report that BMS-790052 inhibits hybrid replicons containing HCV genotype-4 NS5A genes with 50% effective concentrations (EC(50)s) ranging from 7 to 13 pM. NS5A residue 30 was an important site for BMS-790052-selected resistance in the hybrid replicons. Our results support the potential of BMS-790052 as a valuable component of combination therapy for HCV genotype-4 chronic infection.
摘要
BMS-790052 是一种针对非结构蛋白 NS5A 的强效丙型肝炎病毒 (HCV) 复制复合物抑制剂，其对 HCV 基因型-1 的抗病毒特性已得到充分描述。在这里，我们报告 BMS-790052 可抑制含有 HCV 基因型-4 NS5A 基因的杂交复制子，其 50%有效浓度 (EC(50)s) 范围为 7 至 13 pM。NS5A 残基 30 是 BMS-790052 在杂交复制子中选择耐药性的重要位点。我们的结果支持 BMS-790052 作为 HCV 基因型-4 慢性感染联合治疗有价值的组成部分的潜力。
相似文献
1
In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.BMS-790052 对 HCV 基因 4 型 NS5A 的体外活性。
Antimicrob Agents Chemother. 2012 Mar;56(3):1588-90. doi: 10.1128/AAC.06169-11. Epub 2011 Dec 27.
2
In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A.体外研究达卡他韦对 HCV 基因 3 型 NS5A 的活性。
Antimicrob Agents Chemother. 2013 Jan;57(1):611-3. doi: 10.1128/AAC.01874-12. Epub 2012 Oct 22.
3
Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures.发现具有二聚体结构的强效丙型肝炎病毒 NS5A 抑制剂。
Antimicrob Agents Chemother. 2011 Aug;55(8):3795-802. doi: 10.1128/AAC.00146-11. Epub 2011 May 16.
4
Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.丙型肝炎病毒1至6型NS5A上的达卡他韦耐药屏障比较：对跨基因型活性的影响
Antimicrob Agents Chemother. 2014 Sep;58(9):5155-63. doi: 10.1128/AAC.02788-14. Epub 2014 Jun 16.
5
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.化学遗传学策略鉴定出一种具有强大临床效果的 HCV NS5A 抑制剂。
Nature. 2010 May 6;465(7294):96-100. doi: 10.1038/nature08960. Epub 2010 Apr 21.
6
Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.来自基因型 1-7 的 HCV 重组变体对 NS5A 抑制剂的敏感性不同，但对干扰素-α的敏感性没有差异。
Gastroenterology. 2011 Mar;140(3):1032-42. doi: 10.1053/j.gastro.2010.11.036. Epub 2010 Nov 25.
7
Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.BMS-790052 治疗的复制子细胞中丙型肝炎病毒 RNA 的清除和耐药性的发展。
Antimicrob Agents Chemother. 2012 Mar;56(3):1350-8. doi: 10.1128/AAC.05977-11. Epub 2012 Jan 3.
8
Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052.通过研究 NS5A 抑制剂 BMS-790052，揭示了 HCV RNA 复制中 NS5A 的不同功能。
J Virol. 2011 Jul;85(14):7312-20. doi: 10.1128/JVI.00253-11. Epub 2011 May 18.
9
Synergistic Activity of Combined NS5A Inhibitors.联合使用的NS5A抑制剂的协同活性。
Antimicrob Agents Chemother. 2015 Dec 28;60(3):1573-83. doi: 10.1128/AAC.02639-15.
10
Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052.基线多态性对丙型肝炎病毒非结构蛋白 5A 复制复合物抑制剂 BMS-790052 耐药性出现的影响。
Hepatology. 2012 Jun;55(6):1692-9. doi: 10.1002/hep.25581.
引用本文的文献
1
Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure.DAAs 治疗失败后丙型肝炎病毒相关慢性肝病中的耐药检测和再治疗选择。
Infection. 2018 Dec;46(6):761-783. doi: 10.1007/s15010-018-1188-3. Epub 2018 Aug 6.
2
Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4.索磷布韦联合达拉他韦治疗伴有或不伴有利巴韦林的慢性丙型肝炎病毒基因型 4 患者的疗效和安全性：真实世界大样本研究结果。
Hepatol Int. 2018 Jul;12(4):348-355. doi: 10.1007/s12072-018-9868-8. Epub 2018 May 12.
3
Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview.达卡他韦治疗丙型肝炎的疗效与安全性概述
J Clin Transl Hepatol. 2016 Dec 28;4(4):336-344. doi: 10.14218/JCTH.2016.00038. Epub 2016 Nov 3.
4
State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization.抗击丙型肝炎病毒的现状、未解决的问题及未来研究方向：筛查、耐药性诊断和免疫的前景
J Immunol Res. 2016;2016:1412840. doi: 10.1155/2016/1412840. Epub 2016 Oct 24.
5
Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis.达卡他韦联合聚乙二醇干扰素-α和利巴韦林治疗慢性丙型肝炎：一项荟萃分析。
Springerplus. 2016 Sep 15;5(1):1569. doi: 10.1186/s40064-016-3218-x. eCollection 2016.
6
Direct anti-HCV agents.直接抗丙型肝炎病毒药物。
Acta Pharm Sin B. 2016 Jan;6(1):26-31. doi: 10.1016/j.apsb.2015.09.008. Epub 2015 Nov 24.
7
Synergistic Activity of Combined NS5A Inhibitors.联合使用的NS5A抑制剂的协同活性。
Antimicrob Agents Chemother. 2015 Dec 28;60(3):1573-83. doi: 10.1128/AAC.02639-15.
8
Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.含达拉他韦的全口服方案治疗丙型肝炎病毒感染。
Hepatol Int. 2016 Mar;10(2):258-66. doi: 10.1007/s12072-015-9668-3. Epub 2015 Nov 5.
9
NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection.丙型肝炎病毒4型感染中NS5A序列异质性与达卡他韦耐药机制
J Infect Dis. 2016 Jan 15;213(2):206-15. doi: 10.1093/infdis/jiv379. Epub 2015 Jul 13.
10
Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding.与丙型肝炎病毒NS5A抑制剂相关的耐药模式对药物结合的了解有限。
Viruses. 2014 Nov 6;6(11):4227-41. doi: 10.3390/v6114227.
本文引用的文献
1
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.BMS-790052（一种非结构蛋白 5A 复制复合物抑制剂）在感染 HCV 基因 1 型的患者中的多剂量递增研究。
Hepatology. 2011 Dec;54(6):1956-65. doi: 10.1002/hep.24609.
2
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.人类对丙型肝炎病毒非结构蛋白 5A 复制复合物抑制剂 BMS-790052 耐药变异的基因型和表型分析：体外和体内相关性。
Hepatology. 2011 Dec;54(6):1924-35. doi: 10.1002/hep.24594.
3
Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052.通过研究 NS5A 抑制剂 BMS-790052，揭示了 HCV RNA 复制中 NS5A 的不同功能。
J Virol. 2011 Jul;85(14):7312-20. doi: 10.1128/JVI.00253-11. Epub 2011 May 18.
4
Management of hepatitis C virus genotype 4: recommendations of an international expert panel.丙型肝炎病毒基因型 4 的管理：国际专家小组的建议。
J Hepatol. 2011 Jun;54(6):1250-62. doi: 10.1016/j.jhep.2010.11.016. Epub 2010 Dec 8.
5
Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.在体外复制子系统中分析丙型肝炎病毒 NS5A 抑制剂 BMS-790052 的耐药性。
Antimicrob Agents Chemother. 2010 Sep;54(9):3641-50. doi: 10.1128/AAC.00556-10. Epub 2010 Jun 28.
6
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.化学遗传学策略鉴定出一种具有强大临床效果的 HCV NS5A 抑制剂。
Nature. 2010 May 6;465(7294):96-100. doi: 10.1038/nature08960. Epub 2010 Apr 21.
7
Identification of hepatitis C virus NS5A inhibitors.鉴定丙型肝炎病毒 NS5A 抑制剂。
J Virol. 2010 Jan;84(1):482-91. doi: 10.1128/JVI.01360-09.
8
euHCVdb: the European hepatitis C virus database.euHCVdb：欧洲丙型肝炎病毒数据库。
Nucleic Acids Res. 2007 Jan;35(Database issue):D363-6. doi: 10.1093/nar/gkl970. Epub 2006 Nov 16.
9
Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay.利用丙型肝炎病毒-牛病毒性腹泻病毒双复制子检测法开发基于细胞的高通量特异性筛选方法。
Antimicrob Agents Chemother. 2005 Apr;49(4):1346-53. doi: 10.1128/AAC.49.4.1346-1353.2005.
10
Genetic diversity and evolution of hepatitis C virus--15 years on.丙型肝炎病毒的遗传多样性与进化——十五年回顾
J Gen Virol. 2004 Nov;85(Pt 11):3173-3188. doi: 10.1099/vir.0.80401-0.
Zotero 插件